Table 2.
Differences in self-reported symptom scores among the cohorts at enrollment (n=368)
| Score | Controls n=106 (28.8%) | AI therapy alone n=158 (42.9%) | Chemotherapy followed by AI therapy n=104 (28.3%) | Statistic | p-value |
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | |||
| BPI average pain | 1.4 (2.30) | 2.0 (2.25) | 2.2 (2.15) | KW=10.5 | 0.005 |
| POMS tension/anxietya | 6.9 (6.11) | 6.8 (5.00) | 9.6 (6.18) | F(2,365)=9.7 | <0.001 |
| POMS fatigue/inertia | 5.6 (5.69) | 5.4 (6.04) | 5.6 (5.32) | KW=0.7 | 0.691 |
| BDI-II | 5.5 (6.38) | 5.0 (5.28) | 6.3 (6.43) | KW=3.4 | 0.183 |
| BCPT symptom checklista | 18.7 (14.65) | 18.8 (13.36) | 21.0 (13.51) | F(2,365)=1.7 | 0.181 |
AI, aromatase inhibitor; SD, standard deviation; BPI, Brief Pain Inventory; KW, Kruskal-Wallis Test; POMS, Profile of Mood States; BDI-II, Beck Depression Inventory II; BCPT, Breast Cancer Prevent Trial symptom checklist.
a
Although actual means and SDs are reported for each group, analysis of variance was performed on the square-root transformed variables for POMS tension-anxiety and BCPT symptom checklist scores.